Although not the primary focus of this study, we believe that using a blocking IL‐6 Ab and the WNT5A antagonist Box5, which will also restore the sensitivity of BRAFi‐R melanoma cells to BRAFi treatment, is a more relevant therapeutic approach from our perspective. This evidence concerns the gene IL6 and melanoma.